A5088832831- Retinal Development and Disorders
- Photoreceptor and optogenetics research
- Virus-based gene therapy research
- HIV Research and Treatment
- bioluminescence and chemiluminescence research
- Retinal Diseases and Treatments
- CRISPR and Genetic Engineering
- Respiratory viral infections research
- Neuroinflammation and Neurodegeneration Mechanisms
- Advanced Fluorescence Microscopy Techniques
- HIV/AIDS Research and Interventions
- Immune Cell Function and Interaction
- Vaccine Coverage and Hesitancy
- Reproductive tract infections research
- Immunodeficiency and Autoimmune Disorders
- Influenza Virus Research Studies
- Herpesvirus Infections and Treatments
- Retinoids in leukemia and cellular processes
- Immune responses and vaccinations
- Animal Virus Infections Studies
Boston VA Research Institute
2020-2021
Harvard University
2019-2021
Howard Hughes Medical Institute
2021
California Institute of Technology
2011-2014
Ragon Institute of MGH, MIT and Harvard
2014
Beth Israel Deaconess Medical Center
2013
Retinitis pigmentosa (RP) is an inherited retinal disease affecting >20 million people worldwide. Loss of daylight vision typically occurs due to the dysfunction/loss cone photoreceptors, cell type that initiates our color and high-acuity vision. Currently, there no effective treatment for RP, other than gene therapy a limited number specific genes. To develop gene-agnostic therapy, we screened 20 genes their ability prolong photoreceptor survival in vivo. Here, report adeno-associated...
Significance Retinitis pigmentosa (RP) is a genetically heterogenous disease that lacks effective treatment. In RP, there degeneration of cone photoreceptors in the eye, often leading to complete blindness. The reasons for remain largely unknown. Development therapies preserve cones and vision patients with particularly mutation-independent manner, would benefit from greater understanding underlying pathological mechanisms. We examined immune responses RP mice during period identified...
Gene therapy with recombinant adeno-associated viral (AAV) vectors is a promising modality for the treatment of variety human diseases. Nonetheless, there remain significant gaps in our understanding AAV vector biology, due part to lack robust methods track capsids and genomes. In this study, we describe novel application signal amplification by exchange reaction fluorescence situ hybridization (SABER-FISH) that enabled visualization quantification individual genomes after administration...
Abstract Retinitis pigmentosa (RP) is an inherited retinal disease, affecting >20 million people worldwide. Loss of daylight vision typically occurs due to the dysfunction/loss cone photoreceptors, cell type that initiates our color and high acuity vision. Currently, there no effective treatment for RP, other than gene therapy a limited number specific disease genes. To develop gene-agnostic therapy, we screened ≈20 genes their ability prolong photoreceptor survival in vivo . Here, report...
Background: Recently, a number of antibodies capable broadly neutralizing HIV have been isolated from infected patients, stimulating efforts to elicit their production in naive individuals.As an alternative vaccination, we recently described vectored immunoprophylaxis (VIP) as approach generating high serum concentrations desired monoclonal antibody mice following single intramuscular injection specialized adeno associated viral vector (AAV).Mice that received VIP encoding b12, VRC01 or...
Background: The RV144 trial showed promise towards the development of an effective HIV vaccine, Antibodies to Env VIV2 loop, Env-specific IgA and HLA class II DQBL*06 allele with high were all significantly associated risk infection.Methods: We used integrated systems biology approach identify novel correlates immunogenicity and/or protection.Env-specific stimulated peripheral blood mononuclear cells from participants test hypothesis that innate pro-inflammatory responses would demarcate...